RxDoctor Payments Data

Edel Alvarez, MD

General Practice · Clearwater, FLNPI 1477930501

Payments from drug & device makers

$2,746in general payments, 2019–2025

Across 60 payments — averaging $45.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$402
  • AstraZeneca$321
  • Abbott$157
  • Otsuka America Pharmaceutical, Inc.$121
  • Neurocrine Biosciences, Inc.$118
  • plus $438 from 9 others

What the payments were for

  • Food & beverage$2,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,746 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$5,266
Medicare patients
17
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$55,839
OzempicSemaglutide17$27,007
XareltoRivaroxaban11$12,480
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,210
FarxigaDapagliflozin Propanediol11$6,148
Breo ElliptaFluticasone/Vilanterol14$5,482
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp20$4,006
Albuterol Sulfate HfaAlbuterol Sulfate94$3,264
Celecoxib114$2,551
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm18$2,365
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen165$2,253
Atorvastatin Calcium261$2,207
Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp22$2,164
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen91$2,077
Gabapentin101$1,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$55,83973 claims
Novo NordiskOzempic, Novolog Mix 70-30$402$29,17139 claims
GSKTrelegy Ellipta, Breo Ellipta$1,189$13,69227 claims
AstraZenecaFarxiga$321$6,14811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →